产品名称Lenalidomide (CC-5013)

简述Inhibitors

纯化98.00%

生物活性Lenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. FDA approved on December 27, 2005.

基因/蛋白名称TNF inhibitor

CAS号191732-72-6

计算分子量259.26

配方C13H13N3O3

保存3 years -20˚C powder;2 years -80˚C in solvent;